Tanner Pharma Group Expands Ex-US Access Program to Provide LEUKINE® for Use in Patients with Respiratory Illness Associated with COVID-19
Tanner Pharma Group (Tanner) today announced expansion of the LEUKINE Access Program (LeAP) as a channel for distribution of LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA in 1991 and now manufactured by Partner Therapeutics (PTx), is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.
PTx recently announced that a clinical trial of Leukine® conducted in Belgium of hospitalized COVID-19 patients suffering from acute hypoxic respiratory failure requiring supplemental oxygen met the primary endpoint of significant improvement in lung function. Improvement in oxygenation of at least 33% or more from baseline was seen in 54% of patients on the LEUKINE® plus standard-of-care (SOC) arm versus 26% of patients on SOC (p=.0147).
Tanner provides a regulatory-compliant pathway to make LEUKINE® available in international markets. If a patient is in a country where LEUKINE® is not available commercially physicians may be able to have Leukine® imported for their patients through named patient supply via LeAP managed by Tanner.
“As demonstrated by these positive clinical trial results, LEUKINE® has the potential to help COVID-19 patients,” said Banks Bourne, CEO of Tanner Pharma Group. “Our team is incredibly honored to be trusted with this important role, and we are mobilized to help patients and clinicians around the world gain access.”
LEUKINE® is currently being assessed in a clinical trial in the United States (NCT04411680) to further measure impact on COVID-19 patients.
For more information about this program or to request access to LEUKINE®, please call +1 704 643 8989 or email email@example.com
About Tanner Pharma Group
Tanner Pharma Group partners with biopharmaceutical companies to provide turn-key solutions that increase patient access to medicines around the world. With an unparalleled blend of local market knowledge and international supply chain expertise across more than 130 countries, Tanner provides tailored solutions to biopharmaceutical companies outside their core markets of focus. For more information, visit www.tannerpharma.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DC-EIG9.4.2021 22:32:12 CEST | Press release
EIG Signs $12.4 Billion Infrastructure Deal with Aramco
SOFTWARE-RÉPUBLIQUE9.4.2021 14:47:14 CEST | Press release
Atos, Dassault Systèmes, Groupe Renault, STMicroelectronics and Thales Join Forces to Create the ‘Software République’: a New Open Ecosystem for Intelligent and Sustainable Mobility
BIAL9.4.2021 14:33:13 CEST | Press release
BIAL Launches New Support Platform to Inspire People With Parkinson’s Disease to Stay Active
TOSHIBA9.4.2021 08:51:04 CEST | Press release
Comment by the Chair of Toshiba’s Board on the Acquisition Proposal
EXSCIENTIA9.4.2021 07:32:05 CEST | Press release
Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials
NORTHERN-DATA-AG8.4.2021 15:18:11 CEST | Press release
Northern Data sells Texas data center operations to Riot Blockchain Inc. for approximately EUR 550 million - operational EBITDA guidance for fiscal year 2021 remains unchanged
MA-SKYHOOK8.4.2021 15:02:10 CEST | Press release
Skyhook to Provide Enhanced Location Services for Microsoft Products and Services
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom